This Amendment No. 1 (“Amendment No. 1”) amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on March 4, 2022, (the “Original Schedule 13D”), with respect to the Class A Common Stock, par value $0.0001 per share of ATI Physical Therapy, Inc., a Delaware corporation (the “Issuer” or the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment No. 1 have the meanings set forth in the Original Schedule 13D.
This Amendment No. 1 amends the Original Schedule 13D as specifically set forth herein.
Item 3. Source and Amount of Funds or Other Consideration.
The purchases of Shares reported herein were made using funds from the working capital of the Knighthead Funds, which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business. A total of approximately $[ ] (excluding brokerage commissions) was paid to acquire the Shares reported in this Amendment No. 1.
Item 4. Purpose of Transaction.
Item 4 is hereby amended to include the following at the end thereof:
On May 6, 2022, Knighthead Distressed Opportunities Fund, L.P. entered into a Securities Purchase Agreement with Caspian Capital LP on behalf of its managed funds, to purchase from Blackstone Alternative Investment Fund Plc (BXIII) and Blackstone Alternative Investment Fund Plc (BXIIIb) an aggregate of (i) 21,219 Penny Warrants and (ii) 19,199 $3 Warrants (together, the “Warrants”). The holders of the Warrants are subject to the terms and conditions of both the Warrant Agreement and the Investors’ Rights Agreement.
This summary is qualified in its entirety by (i) reference to the text of the Warrant Agreement, which is attached as Exhibit 4.1 to the Issuer’s Current Report on Form 8-K filed by the Issuer with the Commission on February 25, 2022 and is incorporated herein by reference and (ii) reference to the text of the Investors’ Rights Agreement, which is attached as Exhibit 10.3 to the Issuer’s Current Report on Form 8-K filed by the Issuer with the Commission on February 25, 2022, and is incorporated herein by reference.
Item 5. Interest in Securities of the Issuer.
(a)—(b) The information relating to the beneficial ownership of the Shares by each of the Reporting Persons set forth in Rows 7 through 13 on each of the cover pages hereto is incorporated by reference herein and is as of the date hereof. Such information assumes there are 207,148,839 shares of Class A Common Stock issued and outstanding as of August 4, 2022 as reported on the Issuer’s Form 10-K, filed on August 9, 2022
By virtue of the relationship among the Reporting Persons described in Item 2, each such Reporting Person may be deemed to share the power to vote or direct the vote and to share the power to dispose of or direct the disposition of the Shares as set forth in rows 7 through 13 of the cover pages of this Statement. The filing of this Statement shall not be construed as an admission that any such Reporting Person, Mr. O’Hara, Mr. Wagner or Mr. Cohen is, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this Statement.
(c) Except as otherwise set forth in this Statement, including, but not limited to, the Class A Common Stock transactions described in Exhibit A to this Schedule 13D/A, none of the Reporting Persons has effected any transactions in the Class A Common Stock during the past 60 days.
(d) Except as stated within this Item 5, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the Class A Common Stock of the Issuer reported by this Statement.
(e) Inapplicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
The information set forth in or incorporated by reference in Item 4 of this Schedule 13D/A is hereby incorporated by reference in its entirety into this Item 6.